Integrase Inhibitors: all 515 studies that test it

Page 5 of 6. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).CompletedNCT01978782Phase 1
• Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult SubjectsCompletedNCT01967771Phase 1
• Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral DensityCompletedNCT01966822Phase 3
• Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to RaltegravirTerminatedNCT01902186Phase 4
• A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)CompletedNCT01900106Phase 3
• Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV CoinfectionCompletedNCT01900015Phase 4
• Raltegravir for HAM/TSPCompletedNCT01867320Early Phase 1
• An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult SubjectsCompletedNCT01848340Phase 1
• RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected PatientsStatus unknownNCT01829802Phase 4
• Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of MidazolamCompletedNCT01827540Phase 1
• Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral TherapyCompletedNCT01825031Phase 3
• Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.CompletedNCT01779687Phase 1
• A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy SubjectsCompletedNCT01756131Phase 1
• A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult SubjectsCompletedNCT01754116Phase 1
• A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV InfectionStatus unknownNCT01697046Phase 3
• Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir StudyCompletedNCT01679964Phase 4
• Relative Bioavailability Study of GSK1265744 FormulationsCompletedNCT01648257Phase 1
• Evaluation of the Bioequivalence of a Combined Formulated TabletCompletedNCT01622790Phase 1
• Trial to Assess Effect of Raltegravir on HTLV-1 Proviral LoadWithdrawnNCT01620736Phase 2
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult SubjectsCompletedNCT01593046Phase 1
• Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)CompletedNCT01576731Phase 4
• Dolutegravir Expanded Access StudyCompletedNCT01536873Not applicable
• A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy VolunteersCompletedNCT01531647Phase 1
• Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and EthinylestradiolCompletedNCT01498861Phase 1
• Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease InhibitorsCompletedNCT01480713Phase 3
• A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult SubjectsCompletedNCT01467531Phase 1
• Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.CompletedNCT01467518Phase 1
• GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Healthy Male SubjectsCompletedNCT01459315Phase 1
• RAltegravir Switch STudy: Effects on Endothelial RecoveryStatus unknownNCT01453933Phase 4
• Renal Transplantation and Raltegravir in HIV-Infected PatientsCompletedNCT01453192Phase 3
• Drug Interaction Study Between Dolutegravir and PrednisoneCompletedNCT01425099Phase 1
• The Effect of Intermittent Rifampicin on RaltegravirCompletedNCT01424826Phase 1
• GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female SubjectsCompletedNCT01404806Phase 1
• Relative Bioavailability Study of a Pediatric Granule Formulation of DolutegravirCompletedNCT01382238Phase 1
• Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination TabletsCompletedNCT01366547Phase 1
• Dolutegravir Renal Impairment StudyCompletedNCT01353716Phase 1
• A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese SubjectsCompletedNCT01332565Phase 1
• Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected PatientsStatus unknownNCT01318096Not applicable
• Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic CirrhosisCompletedNCT01289951Phase 1
• TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and RaltegravirCompletedNCT01288755Phase 1
• A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.WithdrawnNCT01283100Phase 1
• Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and NeckCompletedNCT01275183Early Phase 1
• Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.CompletedNCT01258439Phase 4
• TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and RaltegravirCompletedNCT01241773Phase 1
• Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infectionCompletedNCT01231685Phase 2
• GSK1349572 Hepatic Impairment StudyCompletedNCT01231529Phase 1
• Safety Study of Raltegravir in HIV/HCV Co-infected PatientsWithdrawnNCT01225705Phase 4
• A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy SubjectsCompletedNCT01214993Phase 1
• Measurement of Plasma and Intracellular Concentrations of RaltegravirCompletedNCT01214486Not applicable
• GSK1349572 Drug Interaction Study With Fosamprenavir/RitonavirCompletedNCT01209065Phase 1
• Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese PatientsStatus unknownNCT01201239Phase 4
• A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear CellsWithdrawnNCT01173510Phase 4
• Pilot Study of Raltegravir Lipodystrophy IISPStatus unknownNCT01164605Not applicable
• Pharmacokinetics of Low Dose RaltegravirCompletedNCT01159132Phase 2
• Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once DailyCompletedNCT01121809Phase 4
• Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV InfectionCompletedNCT01114425Phase 3
• Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug UsersStatus unknownNCT01105611Phase 4
• A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult SubjectsCompletedNCT01101893Phase 1
• GSK1349572 Drug Interaction Study With EfavirenzCompletedNCT01098526Phase 1
• GSK1349572 Relative Bioavailability StudyCompletedNCT01098513Phase 1
• Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With MenCompletedNCT01087840Phase 4
• Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy VolunteersCompletedNCT01068925Phase 1
• Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected PatientsCompletedNCT01059422Phase 4
• Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected SubjectsCompletedNCT01047995Phase 1
• A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone MaintenanceStatus unknownNCT01042652Not applicable
• Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)CompletedNCT01033760Phase 3
• Raltegravir in Patients With End Stage Liver Disease and in Transplant RecipientsCompletedNCT01022476Phase 1/2
• Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected PatientsStatus unknownNCT01013987Phase 4
• Study to Assess Cardiac Conduction of GSK1349572CompletedNCT00996021Phase 1
• Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIVCompletedNCT00995241Phase 4
• Europe-Africa Research Network for Evaluation of Second-line TherapyCompletedNCT00988039Phase 3
• Effect of Antacids on the Pharmacokinetics of RaltegravirCompletedNCT00944307Phase 1
• GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose StudyCompletedNCT00942136Phase 1
• Simplification From Protease Inhibitors to RaltegravirStatus unknownNCT00941083Phase 4
• IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected PatientsCompletedNCT00935480Phase 3
• DDI Study of Etravirine and GSK1265744CompletedNCT00920296Phase 1
• GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and AtazanavirCompletedNCT00883935Phase 1
• Raltegravir and Atazanavir Dosing Strategy StudyCompletedNCT00874523Phase 3
• GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/RitonavirCompletedNCT00867152Phase 1
• Raltegravir Activity In Lymphoid TissuesWithdrawnNCT00863668Not applicable
• A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572CompletedNCT00858455Phase 1
• Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active TuberculosisCompletedNCT00822315Phase 2
• Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.CompletedNCT00812318Phase 1
• The Effect of Rifapentine on RaltegravirCompletedNCT00809718Phase 1
• Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 GenotypeCompletedNCT00808184Phase 4
• Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1CompletedNCT00807443Phase 2
• Drug Interaction Study Between Raltegravir And UK-453,061CompletedNCT00784420Phase 1
• Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1TerminatedNCT00781287Phase 4
• GSK1349572 Drug Interaction Study With Protease InhibitorsCompletedNCT00774735Phase 1
• GSK1349572 Drug Interaction Study With EtravirineCompletedNCT00774111Phase 1
• Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed ProductCompletedNCT00773708Phase 4
• Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy VolunteersStatus unknownNCT00772720Phase 1
• Raltegravir and Ezetimibe PK StudyCompletedNCT00772551Phase 1
• Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected PatientsCompletedNCT00752037Phase 4
• Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current TreatmentStatus unknownNCT00751153Phase 4
• Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.CompletedNCT00746499Phase 1
• Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected SubjectsStatus unknownNCT00740064Phase 4
• Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART RegimenCompletedNCT00738569Not applicable
• GSK1349572 Drug Interaction With TenofovirCompletedNCT00726336Phase 1
• HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in SpainCompletedNCT00685191Phase 4

← Integrase Inhibitors overview